The FDA released the final batch of documents it relied upon in licensing Pfizer’s Comirnaty COVID-19 vaccine for ages 16 and up—more than 800 days after the agency approved the shot.
The documents are “finally in the hands of the public, where they belong,” the Informed Consent Action Network said in a press release. “Now, independent scientists and researchers can see everything FDA saw when it made its decision that this vaccine was ‘safe and effective.'”
FDA Knew Safety Monitoring System Was ‘Not Sufficient’
Federal health agencies claim COVID-19 vaccines are part of the “most intensive vaccine safety monitoring effort in U.S. history,” with “continuous” and “robust” safety monitoring that helps ensure that the vaccine’s benefits outweigh any risks. Yet the final documents released from Pfizer’s biologic product file reveal the agency knew its safety monitoring program was not sufficient to assess the serious risks of myocarditis and pericarditis associated with Pfizer’s COVID-19 vaccine.“The CBER Sentinel Program is NOT sufficient to assess the serious risks of myocarditis and pericarditis, and subclinical myocarditis associated with COMIRNATY (BNT162b2) in lieu of PMR safety studies under FDAAA [Food and Drug Administration Amendments Act].
“At the time of BLA [Biologics License Application] approval, the data sources in the CBER Sentinel Program are not sufficient to identify the outcomes due to lack of sufficient power to assess the magnitude of risk in patients 12-30 years of age. In addition, CBER Sentinel Program is not sufficient to follow up cases for recovery status and long-term sequelae, or for identification and characterization of subclinical myocarditis cases.”
Cardiac Disorders Higher in Vaccine Trial Group
According to an Aug. 23, 2021, BLA Clinical Review Memorandum, there were more cardiac disorders in trial participants who received Pfizer’s COVID-19 vaccine compared to the placebo group and more instances of tachycardia in the younger vaccinated age group.Cardiac conditions were reported as the cause of death in nine participants 25 to 128 days after having received at least one dose of Pfizer’s COVID-19 vaccine, including seven cases of cardiac arrest, one case of cardiovascular disease, and one case of congestive heart failure.
Five cardiac-related deaths in the placebo group occurred 15 to 81 days after having received a placebo, including two cases of myocardial infarction, one aortic rupture, and two cardiac arrests.
“Because COVID-19 mRNA and its Spike protein are found in the human heart at autopsy causing inflammation and heart damage, it is incontrovertible that the COVID-19 vaccines are cardiotoxic,” cardiologist Dr. Peter McCullough told The Epoch Times in an email.
“Younger individuals with healthy hearts take up more of the damaging vaccine into the cardiac tissue resulting in symptoms of chest pain, palpitations, fluctuations in blood pressure, dizziness, and sadly, some, end up with cardiac arrest either during exercise or in the early morning waking hours. At both time periods, an internal surge of adrenalin appears to be the trigger for the fatal arrhythmia in those with COVID-19 vaccine myocarditis,” he added.
Despite nearly double the number of reported cardiac events in vaccine recipients versus placebo recipients, the FDA concluded the deaths were “unlikely to be related to vaccination.”
Vaccines Released Despite Manufacturing Issues
According to the Pfizer Andover Response to Form FDA 483 included in the released documents, numerous manufacturing issues and inadequacies in quality oversight were also identified. Several batches of COVID-19 vaccines were flagged for deviating from product quality standards, yet the affected batches were released to the public in various lots, the numbers of which were redacted.FDA Acknowledges Vaccine-Associated Enhanced Disease
In its Pharmacovigilance Plan Review Memorandum, the FDA referenced a condition called “vaccine-associated enhanced disease.” According to the journal Vaccine, VAED is the modified presentation of a clinical infection affecting individuals exposed to the wild-type pathogen after having received a vaccine for the same pathogen.In its memo, the FDA stated there are reported deaths in the Vaccine Adverse Event Reporting System (VAERS) in patients reported to be fully vaccinated. Although the agency said that passive surveillance and spontaneous adverse event reporting generally cannot be used to conclude vaccine effectiveness because of the lack of a control group, reporter bias, and underreporting, “severe manifestations and death from COVID-19” increase the possibility of developing VAED, which has “overlapping clinical manifestations with natural SARS-CoV-2 infection, making it difficult to differentiate VAED from severe COVID-19 disease in individual VAERS reports.”
Copy
